Publications by authors named "Marlien Beusink"
Article Synopsis
- The study investigated the effectiveness and safety of two DEX-sparing regimens for preventing delayed nausea in patients receiving moderately emetogenic chemotherapy (MEC) compared to the standard 3-day dexamethasone (DEX) regimen.
- The results showed that both DEX-sparing regimens (ondansetron + DEX + metoclopramide and palonosetron + DEX) were noninferior to the standard DEX regimen in controlling delayed nausea and vomiting, with comparable rates of total control among patients.
- Overall, the findings suggest that DEX-sparing approaches can be as effective as the standard 3-day DEX therapy, which may provide alternative options for managing chemotherapy-induced nausea and vomiting
